- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
CC-90002 is an anti-CD47 antibody. CD47 interacts with signal regulatory protein-α (SIRPα) on macrophages to inhibit cell phagocytosis. It plays an important role in the ability of the immune system to detect nonself from self.1-4 Loss of CD47 expression results in the cell being recognized as foreign for phagocytosis.2,5
Evidence suggests that upregulation of CD47 may allow tumor cells to evade phagocytosis, negatively impacting the function of macrophages that could play a major role in recognition and clearance of tumor cells.5 CD47 has been shown to be expressed and upregulated in various hematologic malignancies, including non-Hodgkin lymphoma.1,3 Preclinical studies have shown that inhibiting CD47 enables phagocytosis of non-Hodgkin lymphoma cells in vitro and reduces non-Hodgkin lymphoma burden in mouse models.3,4